title: Prolonged response to early docetaxel in a patient with biochemical relapse after primary therapy for prostate cancer and incomplete response to androgen suppression therapy.
abstract: Sensitivity to androgen suppression therapy (AST) is a key determinant of survival in patients with non-localized prostate cancer. While an incomplete response to AST is associated with poor survival, additional therapy is typically withheld until obvious cancer progression. It is not known if the application of additional therapy earlier can have a favorable impact on long-term outcomes. We present the case of a patient with biochemically relapsed prostate cancer treated with early docetaxel after initial incomplete response to AST who now has a prolonged response to therapy.
authors.affiliation: Knight Cancer Institute, Oregon Health and Science University, Mail Code L586, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA. barnetch@ohsu.edu
authors.forename: Christine M
authors.initials: CM
authors.lastname: Barnett
authors.forename: Jason F
authors.initials: JF
authors.lastname: Flamiatos
authors.forename: Tomasz M
authors.initials: TM
authors.lastname: Beer
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077143:Docetaxel; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012008:Recurrence; D043823:Taxoids / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel